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The incidence and mortality of breast cancer have been recently inﬂuenced by several new therapeutic strategies. In particular
our knowledge on cancer precursors, risk biomarkers, and genetics has considerably increased, and prevention strategies are
being successfully explored. Since their discovery, retinoids, the natural and synthetic derivatives of vitamin A, have been known
to play a crucial role in cell and tissue diﬀerentiation and their ability to inhibit carcinogenesis has made them the ideal
chemopreventive agents studied in several preclinical and clinical trials. Fenretinide (4-HPR) is the most studied retinoid in breast
cancer chemoprevention clinical trials due to its selective accumulation in breast tissue and its favorable toxicological proﬁle. This
agent showed a signiﬁcative reduction of the incidence of second breast tumors in premenopausal women conﬁrmed after 15-
year followups. Considering Fenretinide protective action, a similar trend on ovarian cancer, this drug warrants reevaluations as a
preventive agent for high-risk young women, such as BRCA-1 and 2 mutation carriers or with a high familial risk. This favorable
eﬀect therefore provides a strong rationale for a primary prevention trial in these unaﬀe c t e dc o h o r to fw o m e n .
1.Introduction
In Western countries, breast cancer is a major concern and
its incidence and mortality rates have been recently inﬂu-
enced by new therapeutic strategies. Our knowledge on
cancer precursors, risk biomarkers, and cancer genetics has
considerably increased, and prevention strategies are being
successfully explored. Unfortunately, over the last decade,
breast cancer prevention has been mainly focused on
endocrine therapies using selective estrogen receptors mod-
ulators (SERMs) and aromatase inhibitors (AIs). Available
preventive strategies for nonhormonal breast malignancies,
more frequently expressed in BRCA mutation carriers and,
in general, in high-risk population, are needed. For these
reasons, a great number of novel chemopreventative agents
are currently under investigation in order to evaluate their
eﬃcacy in this particular cohort of patients.
2. Retinoids
In accordance with their recognized role in the regulation of
cell growth, diﬀerentiation, apoptosis, and their recognized
inhibitory eﬀect on cell growth in ER positive and negative
breast cancer cells, retinoids (either natural or synthetic
compounds structurally related to vitamin A) have long
been studied for their chemotherapeutic eﬀect and for
their chemopreventive potential in breast cancer setting.
Only recently, retinoids have also been applied in this
unaﬀected high-risk population and they have demonstrated
to be able to suppress tumor promotion and modify some
properties of fully transformed malignant cells by activating
and/orrepressingspeciﬁcgenes[1].Retinoidsinitiateligand-
induced dimerization of retinoid acid receptors (RARα, β,
and γ) and retinoid X receptors (RXRα, β,a n dγ). Sub-
sequently, receptors bind to retinoid response elements on2 Journal of Biomedicine and Biotechnology
DNA, and they initiate transactivation of retinoids response
target genes [2]. Retinoid receptors are expressed in both
normal and malignant breast epithelial cells and are critical
for normal development. The mechanism by which retinoids
inhibit breast cell growth has not been completely elucidated
yet. Given the role played by RAR-β in the carcinogenesis
of diﬀerent tumors, its regulation by retinoids has also been
advocated as a putative mechanism of action of these agents
[3]. However, they have been shown to aﬀect multiple signal
transduction pathways, including IGF, TGFβ, and AP-1-
dependent pathways [4–8], as showed in Figure 1.
Several preclinical models suggest that retinoids inhibit
mammary carcinogenesis in carcinogen-treated rats and
in transgenic mice [9–11]. Recently, in order to reduce
retinoids’ side eﬀects, RXR-selective retinoids, commonly
known as rexinoids, have been studied as cancer preventive
agents. In particular, preclinical studies have demonstrated
that these compounds maintain retinoids’ chemopreventive
eﬀect, but have greatly reduced toxicity [12].9cRA,aretinoid
bindingbothRARandRXR,hassigniﬁcantlydelayedtheER-
negative tumor development in SV40 tag mice and MNU-
treated rats [13], although it induced signiﬁcant cutaneous
toxicity. In contrast, a RXR-selective retinoid, LGD1069,
or bexarotene (Targretin), has suppressed both ER-positive
and ER-negative tumor development with minimal toxicity
[14, 15].
3.Fenretinide(4-HPR)
One of the most promising retinoids to be used in
chemoprevention trials is the synthetic amide of retinoic
acid fenretinide, N-4-hydroxyphenyl retinamide (4-HPR)
(Figure 2).
Fenretinide was ﬁrst synthesized by Gander in the late
1960sintheUnitedStates.Itsbiologicactivitywasassayedby
Sporn et al., who also showed the preferential accumulation
of this drug in the breast, instead of in the liver [30].
The inhibition of chemically induced mammary carcinoma
in rats by fenretinide was ﬁrst described in 1979 [31].
Since then, promising in vitro data and a favorable toxicity
proﬁle compared with that of other retinoids have led to
the extensive study of fenretinide in chemoprevention trials
targeting diﬀerent organs [32].
Fenretinide has been found to have signiﬁcant chemo-
preventive action in a large variety of in vitro and in
vivo systems. Both fenretinide and its major metabolite,
4-metoxyphenyl retinamide (MPR), selectively accumulate
in the human breast [33]. It should be noticed that some
fenretinide-basedtoxicitiescouldbeduealsotoitshydrolysis
so that it returns to retinoic acid in vivo [34]. Nevertheless, it
remains a fascinating candidate for breast cancer chemopre-
vention.
4. Mechanismof Action
High-dose fenretinide is cytotoxic for a variety of diﬀerent
tumor cells in preclinical studies [35–37], although its accu-
rate mechanism of action is not yet completely understood.
However, it has been proposed that it might exert its
inhibitory eﬀects by means of both receptor-dependent and
-independent mechanism (Table 1,[ 16–18]).
Although RAR inﬂuence on fenretinide action is highly
debated, recent evidence would support the hypothesis
according to which a mechanism does not require such
relationship. In particular, we would stress the importance
of the studies carried out by Giandomenico et al. [19],
explaining the role of the stable expression of the dominant
negative RARα; by Anding et al. [20], showing that the use of
a RAR panantagonist inﬂuences an unhydrolyzable analogue
of 4-HPR by inducing apoptosis with an independent RAR
signaling pathway; by D Elia et al. [21], assuming resistance
to diﬀerential responsiveness is present in diﬀerent cell lines
thus indicating that Fenretinide may act through diﬀerent
receptor types. All of these ﬁndings seem to diminish the
importance of RAR role.
Fenretinide characteristic feature is the ability to inhibit
cell growth through the induction of apoptosis rather than
diﬀerentiation, an eﬀect that is strikingly diﬀerent from
that of the all-trans retinoic acid [22]. Moreover, 4-HPR-
mediated apoptosis seems to be tissue-speciﬁc, so that
multiple mechanisms might operate within speciﬁc tissues
[17]. For example, in ovarian carcinoma cell lines, retinoids
may induce apoptosis through the depolarization of the
mitochondrial membrane and activation of caspase pathway
[23, 24], while in the breast and in others cell lines apoptosis
seems to be related with a direct molecular interaction with
tubulin [25]. Moreover, reactive oxygen species (ROS), such
as hydrogen peroxide and superoxide, seem to be critical
in mediating apoptosis in diﬀerent cancer cell types [26–
28]. The ability to increase ROS levels, in particular nitric
oxide (NO) by NO synthases (NOS) over the elevation
of sphingolipid ceramide levels [29], has been suggested
as an explanation of the apoptotic eﬀect of fenretinide.
Recently, fenretinide has been shown to be able to induce
NO-mediated apoptosis in breast cancer (BRCA-1)-mutated
breast cancer cells [42].
Additional mechanisms are under investigations, such as
the ability to inhibit cell growth by reducing the expression
of growth-stimulating factors or by inducing the expression
of growth-inhibitory factors.
A recent proposed surrogate biomarker of fenretinide
eﬃcacy is circulating insulin-like growth factor 1 (IGF1).
The IGF system plays a pivotal role in cell proliferation
of both epithelial and mesenchymal tissues by stimulating
mitosis, protecting cells from apoptosis, and maintaining
transformed phenotype [43]. Large prospective studies have
shown that high circulating levels of IGF1 and lower levels
of its major binding protein (IGFBP-3) are associated with a
higher risk of developing subsequent premenopausal breast
cancer and prostate, lung, and colorectal cancer [44–47].
This indicates that circulating IGF1 is a key regulator of
cell and tumor proliferation for the vast majority of human
epithelial cancer. Fenretinide has been shown to inhibit
IGF1-stimulated growth of breast cancer cell lines (BCCLs)
and to downregulate the IGF system in both ER-positive
and ER-negative BCCL [48]. In addition, fenretinide reduces
plasma IGF1 in early breast cancer [49]. The expression
of HER2 has been recently observed to reduce fenretinideJournal of Biomedicine and Biotechnology 3
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Figure 2: Synthetic retinoid fenretinide.
ability to induce apoptosis in breast cancer cells. Moreover,
researchers found that HER2 uses active human protein
kinase (Akt) to induce cyclooxygenase (COX-2) expression
and that inhibition of Akt or COX-2 increased 4-HPR
induces apoptosis mediated by NO production [50]. Thus,
a combination of 4-HPR with COX-2 inhibitors might be a
new strategy to further investigate breast cancer chemopre-
vention.
5.Pharmacology, Safety,andTolerability
Fenretinide pharmacokinetics and its possible side eﬀects
havebeentestedinseveralstudies.The5-yearadministration
of the Milan study (see below) provided a vast corpus of
information on the long-term safety and tolerability of this
retinoid. As a major side eﬀect, it induced a dose-related
linear decrease of plasma retinol, associated with diminished
retinal adaptation to darkness. In order to minimize this
side eﬀect, a 3-day treatment interruption at the end of each
month was introduced to increase plasma retinol concentra-
tions, allowing the partial recovery of retinal storage.
However,anaccurateandcompleteevaluation oftoxicity
was hampered by the lack of a placebo control group.
Dermatological, gastrointestinal, visual, and ophthalmologic
events were relatively frequent, but were mostly mild. In
a recent analysis of the phase III trial [51], the most
common adverse events were diminished dark adaptation
(cumulative incidence, 19%) and dermatologic disorders
(18.6%), such as skin and mucosal dryness, pruritus, and
urticaria. Less common events were gastrointestinal symp-
toms (13%) and alterations of the ocular surface (10.9%).
Women in the control group complained of diminished
dark adaptation, dermatologic disorders, gastrointestinal
symptoms, and alterations of the ocular surface in 2.9%,4 Journal of Biomedicine and Biotechnology
Table 1: Mechanism of action of Fenretinide (4-HPR). Corresponding references: [16–29].
Mechanism of action Eﬀect
Receptor dependent
RAR-α, β, γ and RXR-α, β, γ (ligand-activated transcription factors) Regulation of growth, diﬀerentiation, and apoptosis
Receptor independent
Generation of ROS: hydrogen peroxide and superoxide
Induction of COX-2 expression by HER2/neu through activation of Akt
Production of nitric oxide by NOS in BRCA 1 mutated breast cancer cells
C-erbB-2 protein and mRNA downregulation
Sphingolipid ceramide elevation and membrane synthesis alterations
Mitochondrial damage with cytochrome-C release, disruption of
mitochondrial transmembrane potential, and ROS generation
Caspases activation
Apoptosis
Induction of growth inhibition factors
Inhibition of growth stimulating factors (IGF-1)
Increased secretion of IGFBPs
TGF-β secretion
Cell growth inhibition
Decreased telomerase activity in MNU-induced mammary tumor and
bronchial epithelium of cigarette smokers Breast cancer development and progression
2.9%, 5.4%, and 3.2% of the cases, respectively. Interestingly,
most side eﬀects decreased with time and were signiﬁcantly
more frequent in postmenopausal women. Importantly, in
contrast to other retinoids, prolonged administration of
fenretinide is not associated with signiﬁcant alterations of
bone mineral density of the forearm [52] .H o w e v e r ,at r e n d
towards an increase in bone resorption markers suggests the
need for further assessment at diﬀerent skeletal sites.
After the completion of a phase I dose-ranging study
[38], the 200mg daily dose was chosen as the safest dose for
prevention, as one case of a pathological electroretinogram
after a 24-week administration was observed with the
300mg/day dose [39]. Higher doses, upto 400mg, have been
used in women with metastatic cancer in combination with
tamoxifen, with no evident toxicity on liver and lipid proﬁle,
but with an increased incidence of nyctalopia [53, 54]. Peak
levels of 4-HPR occur at approximately 6h in adults with
terminal half-life of approx. 13h [39, 55–57].
6.ClinicalTrials
Since both 4-HPR and 4-MPR are selectively accumulated
in the breast, evaluation of fenretinide as a chemopreventive
agent in breast cancer has been particularly attractive. The
mostimportantclinicaltrialswithfenretinidearementioned
in Table 2. As in the therapeutic setting, where drugs combi-
nations are superior to monochemotherapy, the concept of
combining agents with diﬀerent mechanisms of action in the
attempt to increase eﬃcacy while minimizing side eﬀects is a
rational approach in chemoprevention. In preclinical mod-
els, combined administration of fenretinide and tamoxifen
hasprovenadditiveandsynergisticinbothgrowthinhibition
of MCF-7 cells and prevention of MNU-induced mammary
carcinomas [58]. Moreover, the activity of 9-cis-retinoic acid
againstMNU-inducedmammarytumorsinSprague-Dawley
rats is enhanced by the combination with tamoxifen or
raloxifene [11]. The safety and the tolerability of the com-
bination of fenretinide and tamoxifen have been investigated
in clinical trials in metastatic breast cancer patients [53]a n d
in women at increased risk [59]. The concept of combining
agents with diﬀerent mechanisms of action in the attempt
to increase eﬃcacy on complementary molecular targets,
while minimizing side eﬀects is increasingly being pursued
in breast cancer chemoprevention. A clinical randomized,
double-blind, placebo-controlled phase IIb trial with a 2 × 2
factorial design to test this interaction (fenretinide and low-
dose tamoxifen) was conducted at the European Institute of
Oncology [60]. In spite of the favorable eﬀects on plasma
IGF-I levels and mammographic density, this combination
did not reduce breast neoplastic events compared to placebo,
whereas both single agents, particularly fenretinide, showed
numerical reduction in annual odds of breast neoplasms.
Fenretinide (in combination with HRT) was also studied
by our group in 226 postmenopausal healthy women,
randomized in a two-by-two factorial design to either oral
CEE 0.625mg/day or transdermal E2, 50microg/day and to
fenretinide 100mg/twice a day or placebo for 12 months
[61]. Oral CEE showed more favorable changes than trans-
dermalE2oncirculatingbreastcancerriskbiomarkers,while
fenretinide exerted little modulation on most biomarkers.
The most important study where 4-HPR was adminis-
tratedasasingleagentisamulticentricphaseIIIrandomized
trial, coordinated by the Istituto Nazionale dei Tumori in
Milan, started in 1987. Stage I (T1-2 N0) breast cancer
patients, aged 33–70 years, who had been operated on for
breast cancer within the previous 10 years and had received
no systemic adjuvant therapy were eligible [40]. Women
were randomly assigned to receive either no treatment or
fenretinide given orally at a dose of 200mg/day for 5 years.
A placebo-control arm was not included in the study design
because of the large capsule size and the objective nature
of the main outcome measure. A 3-day drug stoppage at
the end of each month was recommended in order to
allow retinol recovery and to minimize dark adaptation
impairment. The main outcome measure was the occurrenceJournal of Biomedicine and Biotechnology 5
Table 2: Clinical trials with fenretinide.
Study Design Treatment End points Outcomes References
Costa et al. (1989) Phase I, R, PC (60)
Orally: 100, 200, and
300mg × 6m o n t h s
subsequently at 200mg
for another 6 months
Tolerability
Recommended dose for
chemoprevention trials of HPR is
200mg/die.
[38]
Formelli et al. (1989) Phase II, R, PC (60)
Orally: 100, 200, and
300mg × 6m o n t h s
subsequently at 200mg
for another 6 months
Pharmacokinetic
HPR treatment lowers retinol and
RPB plasma concentrations. This
eﬀect is related to HPR levels and
is reversible on cessation of HPR
administration.
[39]
Veronesi et al. (1999) Phase III R (2867) Orally 200mg versus no
treatment × 5 years
Second breast
cancer prevention
No statistically signiﬁcant eﬀect
but a possible beneﬁt in
premenopausal women.
[40]
Veronesi et al. (2006) Phase III, R, 15-year
followup (1879)
Orally 200mg versus no
treatment × 5 years;
15-year followup
Second breast
cancer prevention
4-HPR induces a signiﬁcant risk
reduction of second breast cancer
in premenopausal women, which
is remarkable at younger ages, and
persists several years after
treatment cessation.
[41]
HPR: Fenretinide; PC: placebo controlled; R: randomized; RBP: retinol-binding protein.
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Figure 3:Oppositeeﬀectoffenretinideaccordingtomenopausalstatus.Cumulativehazardcurvesforallsecondbreastcancers(contralateral
and ipsilateral) by allocated arm, stratiﬁed by premenopausal women (a) and postmenopausal women (b).
of contralateral breast cancer as ﬁrst malignant event. The
secondary endpoint was the incidence of ipsilateral breast
cancer reappearance, deﬁned as local recurrence in the same
quadrant or the occurrence of a second breast malignancy
in diﬀerent quadrants from the primary tumor. Fenretinide
showed no eﬀect on contralateral breast cancer occurrence
and a nonsigniﬁcant 17% reduction in ipsilateral breast
tumor reappearance. However, a diﬀerent eﬀect was noted
when the analysis was stratiﬁed by menopausal status, with a
beneﬁcialtrendinpremenopausalwomenonbothcontralat-
eral and ipsilateral breast cancer (38%) and a reversed trend
on contralateral breast cancer in postmenopausal women,
as highlighted in Figure 3. Importantly, the protective eﬀect
persisted for up to 15 years (i.e., 10 years after retinoid ces-
sation) [41]. Most notably, the younger the women were, the
greater the beneﬁt of fenretinide. Such beneﬁt was associated6 Journal of Biomedicine and Biotechnology
with a remarkable 50% risk reduction in women aged 40
years or younger, whereas the beneﬁt disappeared after 55
years of age. Interestingly, the incidence of ovarian cancer
during the 5-year intervention period was signiﬁcantly lower
in the treatment arm [62]. This eﬀect has been conﬁrmed
in an important update [63]. This phase III trial suggested
a possible role of fenretinide as a preventive agent acting
at diﬀerent levels of breast carcinogenesis. Admittedly, the
results obtained during the phase III trial on our subgroups
had not been foreseen when the study was planned. While
there are plausible biological explanations for this selective
eﬀect, our ﬁndings are hypothesis generating and do not
haveimmediate practicalclinicalimplications, althoughthey
do provide the rationale for testing the drug’s eﬃcacy in
premenopausal women. Moreover, this protective eﬀect was
suggested in women with a high probability of carrying a
BRCA-1 mutation. Indeed, fenretinide was highly eﬀective
in inhibiting the growth of BRCA-1 mutated breast cancer
cell lines [42]. When considering the protective activity of
fenretinide on second breast cancer in young women and a
similar trend on ovarian cancer, at least during intervention,
it appears that women with germline BRCA-1 and BRCA-2
mutations may be ideal candidates for further investigation
of this drug.
7. FutureStudies
All the collected data as well as fenretinide characteristics
make this drug an excellent candidate for chemoprevention
of the highlighted subgroup, that is, young healthy women
with a high susceptibility to early-onset breast and ovarian
cancer, such as BRCA1/2 mutation carriers or women with a
signiﬁcant familial risk. Since the drug activities are probably
not strictly inﬂuenced by hormonal responsiveness, it may
aﬀectalsohormone nonresponsive cancers.This maybe very
useful particularly in case of BRCA 1 mutation carriers.
Several drugs used in prevention settings are usually
the same as those used for treatment (adjusting dosage
and/or route of administration). This is possible because
their mechanism of actions is also active on early-phase
carcinogenesis and not only on the inhibition of the tumor
growth. This is conﬁrmed by the reduction of second breast
cancer found in the reported studies of Veronesi et al. [40,
41]. These data make 4-HPR a surrogate marker of primary
prevention and a favorable eﬀect of the drug would provide a
strong rationale for a primary prevention trial in unaﬀected
women at high risk for breast cancer. Moreover, because
its action does not seem to be inﬂuenced by the hormonal
status,fenretinidemightbeactiveinhormonenonresponsive
cancer prevention (as occurs in BRCA-1 mutation carriers).
Although we obviously need to verify this hypothesis, we
think it is an intriguing scenario that could be important in
order to identify new pathways related to the eﬃcacy of this
drug.
OurDivisionofCancerPreventionandGeneticsatEuro-
pean Institute of Oncology to Milan has already activated a
new phase III prevention trial addressed to this particular
cohort of women.
BRCA 1/2 carriers,
20% mutation risk, R
Placebo
5 years
Setting: National, multicenter
Samplesize: 764 subjects 
Secondary endpoints: Ovarian ca, biomarkers of carisk
Followup: 10 years
Primary endpoint: Incidence of breast cancer (ER+ and ER−) 
New phase III prevention trial of
4-HPR versus placebo
in young high-risk subjects
and DCIS
Age: 20–46
Fenretinide 
200 mg/d
Figure 4: 4-HPR trial design.
This project is a multicentric randomized phase III
placebo-controlled study. A total of 764 healthy women at
increased breast cancer risk will be randomized to 4-HPR
200mg/day versus placebo for 5 years. The subjects will
be stratiﬁed by participating center and breast cancer risk
(BRCA1 mutation versus BRCA2 versus high risk subjects).
The accrual estimated time is ﬁve years. The design of the
study is explained in Figure 4.
The aim of the proposed trial is to assess the eﬃcacy
of fenretinide, in reducing the incidence of breast cancer
in healthy young premenopausal women at increased famil-
ial/genetic risk for breast cancer; the primary endpoint is
to assess the incidence of histologically diagnosed invasive
breast cancer and ductal intraepithelial neoplasia.
Secondary endpoints are the incidence of other nonin-
vasive breast disorders (i.e., intraepithelial lobular neoplasia
and atypical hyperplasia), ovarian cancer and other cancers.
Moreover, we propose an interdisciplinary research study
tofurtherinvestigatethemechanismsofactionoffenretinide
in preventing breast cancer. Early intermediate biomarkers
of eﬃcacy after 12, 36, and 60 months of treatment,
genetic interactions with breast cancer risk modiﬁers will
be explored with the primary goal to identify molecular
biomarkers of response prediction. In particular, we will
evaluate the percentage change in circulating biomarkers of
the IGF system, androgens, retinol binding protein (RBP-
4), insulin, blood glucose, and VEGF after 12, 36, and 60
months of treatment. In a subgroup of participants, ﬁne
needle aspirate breast biopsy or cells obtained from breast
ductal lavage will be drawn at baseline and after a 12-month
treatment and the percentage change in RAR expression
correlated with apoptosis (caspase-3) and proliferation (Ki-
67).Genotypingofsingle-nucleotidepolymorphisms(SNPs)
linked to breast cancer risk (MTHFR, COMT, GH, IGFBP-3,
AR, and TGF-β genes), degree of methylation of RASSAF1
and RAR β, and circulating progranulin will be assessed. The
results will be correlated with mammographic instrumental
measurements, plasma and tissue biomarkers after 1-year
treatment. Fenretinide and its metabolites will also beJournal of Biomedicine and Biotechnology 7
measured to investigate drug bioavailability and compliance.
Should the results of this trial conﬁrm that fenretinide is
eﬀective in reducing breast and ovarian cancer incidence in
this very high risk population, that this eﬀect lasts for many
years after treatment, and that the tolerability proﬁle is good,
we will have a further preventive chance and a new risk
reduction strategy.
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